ArticleJournal of biochemical and molecular toxicology2026
XDH Inhibits the Progression of Colorectal Cancer via Regulating Ferritinophagy Signaling.
Article in Journal of biochemical and molecular toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Xanthine dehydrogenase (XDH) is involved in the progression of various cancer. This study aimed to investigate its potential in colorectal cancer (CRC). Gene expression was determined using RT-qPCR, Western blot, immunohistochemistry, and immunofluorescence. Cell behaviors were analyzed using CCK-8, colony formation, wound healing, transwell migration, TUNEL, PI staining. In vivo assay was conducted to verify the role of XDH in CRC. Histological analysis was performed using HE staining. We found that XDH was downregulated in CRC. XDH overexpression suppressed proliferation and aggressiveness of CRC cells, whereas XDH knockdown exerted opposite effects. XDH selectively increased purine metabolites and promoted impairment of mitochondrial metabolism. Mechanistically, XDH activated NCOA4-dependent ferritinophagy signaling and drove CRC cells to ferroptosis, which was reversed by 3-MA. Taken together, XDH inhibits the progression of CRC via mediating ferritinophagy and ferroptosis. Therefore, XDH/ferritinophagy may be a potential target for CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.